<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">21157483</PMID>
      <DateCompleted>
        <Year>2011</Year>
        <Month>01</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1471-0080</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2011</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Molecular cell biology</Title>
          <ISOAbbreviation>Nat Rev Mol Cell Biol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>mTOR: from growth signal integration to cancer, diabetes and ageing.</ArticleTitle>
        <Pagination>
          <StartPage>21</StartPage>
          <EndPage>35</EndPage>
          <MedlinePgn>21-35</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/nrm3025</ELocationID>
        <Abstract>
          <AbstractText>In all eukaryotes, the target of rapamycin (TOR) signalling pathway couples energy and nutrient abundance to the execution of cell growth and division, owing to the ability of TOR protein kinase to simultaneously sense energy, nutrients and stress and, in metazoans, growth factors. Mammalian TOR complex 1 (mTORC1) and mTORC2 exert their actions by regulating other important kinases, such as S6 kinase (S6K) and Akt. In the past few years, a significant advance in our understanding of the regulation and functions of mTOR has revealed the crucial involvement of this signalling pathway in the onset and progression of diabetes, cancer and ageing.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zoncu</LastName>
            <ForeName>Roberto</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, Massachusetts 02142, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Efeyan</LastName>
            <ForeName>Alejo</ForeName>
            <Initials>A</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sabatini</LastName>
            <ForeName>David M</ForeName>
            <Initials>DM</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <Acronym>HHMI</Acronym>
            <Agency>Howard Hughes Medical Institute</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R37 AI047389</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA129105</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AI047389</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA103866</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2010</Year>
          <Month>12</Month>
          <Day>15</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Nat Rev Mol Cell Biol</MedlineTA>
        <NlmUniqueID>100962782</NlmUniqueID>
        <ISSNLinking>1471-0072</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015971" MajorTopicYN="N">Gene Expression Regulation, Enzymologic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2010</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2010</Year>
          <Month>12</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2011</Year>
          <Month>1</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">21157483</ArticleId>
        <ArticleId IdType="mid">NIHMS383521</ArticleId>
        <ArticleId IdType="pmc">PMC3390257</ArticleId>
        <ArticleId IdType="doi">10.1038/nrm3025</ArticleId>
        <ArticleId IdType="pii">nrm3025</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253:905–909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1715094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7518356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown EJ, et al.  A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8008069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabers CJ, et al.  Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995;270:815–822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7822316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17613433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16469695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara K, et al.  Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110:177–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DH, et al.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, et al.  Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–1302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15268862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nojima H, et al.  The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem. 2003;278:15461–15464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12604610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schalm SS, Fingar DC, Sabatini DM, Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr Biol. 2003;13:797–806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12747827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wullschleger S, Loewith R, Oppliger W, Hall MN. Molecular organization of target of rapamycin complex 2. J Biol Chem. 2005;280:30697–30704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16002396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancak Y, et al.  The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science. 2008;320:1496–1501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2475333</ArticleId>
            <ArticleId IdType="pubmed">18497260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancak Y, et al.  PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25:903–915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17386266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearce LR, et al.  Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J. 2007;405:513–522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2267312</ArticleId>
            <ArticleId IdType="pubmed">17461779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007;9:316–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17277771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frias MA, et al.  mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol. 2006;16:1865–1870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16919458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Q, Inoki K, Ikenoue T, Guan KL. Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev. 2006;20:2820–2832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1619946</ArticleId>
            <ArticleId IdType="pubmed">17043309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo SY, et al.  PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem. 2007;282:25604–25612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17599906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson TR, et al.  DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137:873–886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758791</ArticleId>
            <ArticleId IdType="pubmed">19446321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. Structure of the human mTOR complex I and its implications for rapamycin inhibition. Mol Cell. 2010;38:768–774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2887672</ArticleId>
            <ArticleId IdType="pubmed">20542007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacinto E, et al.  Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004;6:1122–1128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15467718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbet NC, et al.  TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell. 1996;7:25–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC278610</ArticleId>
            <ArticleId IdType="pubmed">8741837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Helliwell SB, Howald I, Barbet N, Hall MN. TOR2 is part of two related signaling pathways coordinating cell growth in Saccharomyces cerevisiae. Genetics. 1998;148:99–112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1459785</ArticleId>
            <ArticleId IdType="pubmed">9475724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zheng XF, Florentino D, Chen J, Crabtree GR, Schreiber SL. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell. 1995;82:121–130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7606777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 1996;273:239–242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8662507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loewith R, et al.  Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell. 2002;10:457–468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12408816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159–168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16603397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown EJ, et al.  Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature. 1995;377:441–441.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7566123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara K, et al.  Regulation of eIF-4E BP1 phosphorylation by mTOR. J Biol Chem. 1997;272:26457–26463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9334222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>von Manteuffel SR, Gingras AC, Ming XF, Sonenberg N, Thomas G. 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. Proc Natl Acad Sci U S A. 1996;93:4076–4080.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC39489</ArticleId>
            <ArticleId IdType="pubmed">8633019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009;10:307–318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19339977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haghighat A, Mader S, Pause A, Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J. 1995;14:5701–5709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC394685</ArticleId>
            <ArticleId IdType="pubmed">8521827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeno P, Ballou LM, Novak-Hofer I, Thomas G. Identification and characterization of a mitogen-activated S6 kinase. Proc Natl Acad Sci U S A. 1988;85:406–410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC279557</ArticleId>
            <ArticleId IdType="pubmed">3257566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lenz G, Avruch J. Glutamatergic regulation of the p70S6 kinase in primary mouse neurons. J Biol Chem. 2005;280:38121–38124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16183639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma XM, Yoon SO, Richardson CJ, Julich K, Blenis J. SKAR links pre-mRNA splicing to mTOR/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell. 2008;133:303–313.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18423201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson KF, Wu WJ, Cerione RA. Cdc42 stimulates RNA splicing via the S6 kinase and a novel S6 kinase target, the nuclear cap-binding complex. J Biol Chem. 2000;275:37307–37310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10973943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell. 2005;123:569–580.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16286006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shahbazian D, et al.  The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J. 2006;25:2781–2791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1500846</ArticleId>
            <ArticleId IdType="pubmed">16763566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannan KM, et al.  mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol. 2003;23:8862–8877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC262650</ArticleId>
            <ArticleId IdType="pubmed">14612424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayer C, Zhao J, Yuan X, Grummt I. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev. 2004;18:423–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC359396</ArticleId>
            <ArticleId IdType="pubmed">15004009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Claypool JA, et al.  Tor pathway regulates Rrn3p-dependent recruitment of yeast RNA polymerase I to the promoter but does not participate in alteration of the number of active genes. Mol Biol Cell. 2004;15:946–956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC329406</ArticleId>
            <ArticleId IdType="pubmed">14595104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin DE, Soulard A, Hall MN. TOR regulates ribosomal protein gene expression via PKA and the Forkhead transcription factor FHL1. Cell. 2004;119:969–979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15620355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schawalder SB, et al.  Growth-regulated recruitment of the essential yeast ribosomal protein gene activator Ifh1. Nature. 2004;432:1058–1061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15616569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. Annu Rev Genet. 2009;43:67–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2831538</ArticleId>
            <ArticleId IdType="pubmed">19653858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noda T, Ohsumi Y. Tor, a phosphatidylinositol kinase homologue, controls autophagy in yeast. J Biol Chem. 1998;273:3963–3966.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9461583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thoreen CC, et al.  An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1. J Biol Chem. 2009;284:8023–8032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2658096</ArticleId>
            <ArticleId IdType="pubmed">19150980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamada Y, et al.  Tor-mediated induction of autophagy via an Apg1 protein kinase complex. J Cell Biol. 2000;150:1507–1513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2150712</ArticleId>
            <ArticleId IdType="pubmed">10995454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosokawa N, et al.  Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell. 2009;20:1981–1991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2663915</ArticleId>
            <ArticleId IdType="pubmed">19211835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jung CH, et al.  ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell. 2009;20:1992–2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2663920</ArticleId>
            <ArticleId IdType="pubmed">19225151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara T, et al.  FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. J Cell Biol. 2008;181:497–510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2364687</ArticleId>
            <ArticleId IdType="pubmed">18443221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosokawa N, et al.  Atg101, a novel mammalian autophagy protein interacting with Atg13. Autophagy. 2009;5:973–979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19597335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kamada Y, et al.  Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization. Mol Cell Biol. 2005;25:7239–7248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1190227</ArticleId>
            <ArticleId IdType="pubmed">16055732</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt A, Bickle M, Beck T, Hall MN. The yeast phosphatidylinositol kinase homolog TOR2 activates RHO1 and RHO2 via the exchange factor ROM2. Cell. 1997;88:531–542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9038344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Facchinetti V, et al.  The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J. 2008;27:1932–1943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2486276</ArticleId>
            <ArticleId IdType="pubmed">18566586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1) Biochem J. 2008;416:375–385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18925875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikenoue T, Inoki K, Yang Q, Zhou X, Guan KL. Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J. 2008;27:1919–1931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2486275</ArticleId>
            <ArticleId IdType="pubmed">18566587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–1101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15718470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA, et al.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006;11:859–871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17141160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Soukas AA, Kane EA, Carr CE, Melo JA, Ruvkun G. Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. Genes Dev. 2009;23:496–511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2648650</ArticleId>
            <ArticleId IdType="pubmed">19240135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA, et al.  mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell. 2009;15:148–159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2701381</ArticleId>
            <ArticleId IdType="pubmed">19185849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara K, et al.  Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem. 1998;273:14484–14494.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9603962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang X, Campbell LE, Miller CM, Proud CG. Amino acid availability regulates p70 S6 kinase and multiple translation factors. Biochem J. 1998;334(Pt 1):261–267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1219687</ArticleId>
            <ArticleId IdType="pubmed">9693128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol. 2008;10:935–945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2711503</ArticleId>
            <ArticleId IdType="pubmed">18604198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancak Y, et al.  Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell. 2010;141:290–303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3024592</ArticleId>
            <ArticleId IdType="pubmed">20381137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saucedo LJ, et al.  Rheb promotes cell growth as a component of the insulin/TOR signalling network. Nat Cell Biol. 2003;5:566–571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12766776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stocker H, et al.  Rheb is an essential regulator of S6K in controlling cell growth in Drosophila. Nat Cell Biol. 2003;5:559–565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12766775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binda M, et al.  The Vam6 GEF controls TORC1 by activating the EGO complex. Mol Cell. 2009;35:563–573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19748353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubouloz F, Deloche O, Wanke V, Cameroni E, De Virgilio C. The TOR and EGO protein complexes orchestrate microautophagy in yeast. Mol Cell. 2005;19:15–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15989961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao M, Kaiser CA. A conserved GTPase-containing complex is required for intracellular sorting of the general amino-acid permease in yeast. Nat Cell Biol. 2006;8:657–667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16732272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zurita-Martinez SA, Puria R, Pan X, Boeke JD, Cardenas ME. Efficient Tor signaling requires a functional class C Vps protein complex in Saccharomyces cerevisiae. Genetics. 2007;176:2139–2150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1950620</ArticleId>
            <ArticleId IdType="pubmed">17565946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urano J, Tabancay AP, Yang W, Tamanoi F. The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake. J Biol Chem. 2000;275:11198–11206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10753927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12172553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell. 2002;10:151–162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potter CJ, Pedraza LG, Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol. 2002;4:658–665.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12172554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garami A, et al.  Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell. 2003;11:1457–1466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12820960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17:1829–1834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC196227</ArticleId>
            <ArticleId IdType="pubmed">12869586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, et al.  Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol. 2003;5:578–581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12771962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tee AR, Manning BD, Roux PP, Cantley LC, Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol. 2003;13:1259–1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12906785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao X, Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev. 2001;15:1383–1392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC312704</ArticleId>
            <ArticleId IdType="pubmed">11390358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell. 2001;105:345–355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11348591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai SL, et al.  Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol. 2006;173:279–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2063818</ArticleId>
            <ArticleId IdType="pubmed">16636147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Inoki K, Yeung R, Guan KL. Regulation of TSC2 by 14-3-3 binding. J Biol Chem. 2002;277:44593–44596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12364343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovacina KS, et al.  Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem. 2003;278:10189–10194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12524439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem. 2007;282:24514–24524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17604271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oshiro N, et al.  The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem. 2007;282:20329–20339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3199301</ArticleId>
            <ArticleId IdType="pubmed">17517883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005;121:179–193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15851026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castilho RM, Squarize CH, Chodosh LA, Williams BO, Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell. 2009;5:279–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2939833</ArticleId>
            <ArticleId IdType="pubmed">19733540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, et al.  TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006;126:955–968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16959574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gangloff YG, et al.  Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol. 2004;24:9508–9516.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC522282</ArticleId>
            <ArticleId IdType="pubmed">15485918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murakami M, et al.  mTOR is essential for growth and proliferation in early mouse embryos and embryonic stem cells. Mol Cell Biol. 2004;24:6710–6718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC444840</ArticleId>
            <ArticleId IdType="pubmed">15254238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dennis PB, et al.  Mammalian TOR: a homeostatic ATP sensor. Science. 2001;294:1102–1105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11691993</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardie DG. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol. 2007;8:774–785.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17712357</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Zhu T, Guan KL. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14651849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 2004;18:1533–1538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC443516</ArticleId>
            <ArticleId IdType="pubmed">15231735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gwinn DM, et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30:214–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2674027</ArticleId>
            <ArticleId IdType="pubmed">18439900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene. 2006;25:6373–6383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17041623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brugarolas J, et al.  Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893–2904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC534650</ArticleId>
            <ArticleId IdType="pubmed">15545625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reiling JH, Hafen E. The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 2004;18:2879–2892.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC534649</ArticleId>
            <ArticleId IdType="pubmed">15545626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng Z, et al.  The regulation of AMPK beta1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res. 2007;67:3043–3053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17409411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw RJ, et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6:91–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15261145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Budanov AV, Karin M. p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell. 2008;134:451–460.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758522</ArticleId>
            <ArticleId IdType="pubmed">18692468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Charest PG, et al.  A Ras signaling complex controls the RasC-TORC2 pathway and directed cell migration. Dev Cell. 2010;18:737–749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2893887</ArticleId>
            <ArticleId IdType="pubmed">20493808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee S, et al.  TOR complex 2 integrates cell movement during chemotaxis and signal relay in Dictyostelium. Mol Biol Cell. 2005;16:4572–4583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1237065</ArticleId>
            <ArticleId IdType="pubmed">16079174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell. 2004;15:1101–1111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC363084</ArticleId>
            <ArticleId IdType="pubmed">14699058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mitochondria by mitophagy. Arch Biochem Biophys. 2007;462:245–253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2756107</ArticleId>
            <ArticleId IdType="pubmed">17475204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuma A, et al.  The role of autophagy during the early neonatal starvation period. Nature. 2004;432:1032–1036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15525940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh R, et al.  Autophagy regulates lipid metabolism. Nature. 2009;458:1131–1135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2676208</ArticleId>
            <ArticleId IdType="pubmed">19339967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu L, et al.  Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature. 2010;465:942–946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2920749</ArticleId>
            <ArticleId IdType="pubmed">20526321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zid BM, et al.  4E-BP extends lifespan upon dietary restriction by enhancing mitochondrial activity in Drosophila. Cell. 2009;139:149–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2759400</ArticleId>
            <ArticleId IdType="pubmed">19804760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunningham JT, et al.  mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. Nature. 2007;450:736–740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18046414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polak P, et al.  Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab. 2008;8:399–410.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19046571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yeh WC, Bierer BE, McKnight SL. Rapamycin inhibits clonal expansion and adipogenic differentiation of 3T3-L1 cells. Proc Natl Acad Sci U S A. 1995;92:11086–11090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC40576</ArticleId>
            <ArticleId IdType="pubmed">7479942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gagnon A, Lau S, Sorisky A. Rapamycin-sensitive phase of 3T3-L1 preadipocyte differentiation after clonal expansion. J Cell Physiol. 2001;189:14–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11573200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147–1156.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8001151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JE, Chen J. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004;53:2748–2756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15504954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang HH, et al.  Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One. 2009;4:e6189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2703782</ArticleId>
            <ArticleId IdType="pubmed">19593385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Bacquer O, et al.  Elevated sensitivity to diet-induced obesity and insulin resistance in mice lacking 4E-BP1 and 4E-BP2. J Clin Invest. 2007;117:387–396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1783830</ArticleId>
            <ArticleId IdType="pubmed">17273556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JB, Spiegelman BM. ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Dev. 1996;10:1096–1107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8654925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim JB, Wright HM, Wright M, Spiegelman BM. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A. 1998;95:4333–4337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC22489</ArticleId>
            <ArticleId IdType="pubmed">9539737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Porstmann T, et al.  SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8:224–236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2593919</ArticleId>
            <ArticleId IdType="pubmed">18762023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dowell P, Otto TC, Adi S, Lane MD. Convergence of peroxisome proliferator-activated receptor gamma and Foxo1 signaling pathways. J Biol Chem. 2003;278:45485–45491.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12966085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakae J, et al.  Regulation of insulin action and pancreatic beta-cell function by mutated alleles of the gene encoding forkhead transcription factor Foxo1. Nat Genet. 2002;32:245–253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12219087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Um SH, et al.  Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431:200–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15306821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newgard CB, et al.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab. 2009;9:311–326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3640280</ArticleId>
            <ArticleId IdType="pubmed">19356713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cota D, et al.  Hypothalamic mTOR signaling regulates food intake. Science. 2006;312:927–930.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16690869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsieh AC, et al.  Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell. 2010;17:249–261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2901095</ArticleId>
            <ArticleId IdType="pubmed">20227039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wendel HG, et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428:332–337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15029198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wendel HG, et al.  Dissecting eIF4E action in tumorigenesis. Genes Dev. 2007;21:3232–3237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2113024</ArticleId>
            <ArticleId IdType="pubmed">18055695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–777.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17882277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qu X, et al.  Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112:1809–1820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC297002</ArticleId>
            <ArticleId IdType="pubmed">14638851</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue Z, Jin S, Yang C, Levine AJ, Heintz N. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A. 2003;100:15077–15082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC299911</ArticleId>
            <ArticleId IdType="pubmed">14657337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marino G, et al.  Tissue-specific autophagy alterations and increased tumorigenesis in mice deficient in Atg4C/autophagin-3. J Biol Chem. 2007;282:18573–18583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17442669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008;134:703–707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18775299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carracedo A, et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest. 2008;118:3065–3074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2518073</ArticleId>
            <ArticleId IdType="pubmed">18725988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang H, et al.  PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest. 2007;117:730–738.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1784000</ArticleId>
            <ArticleId IdType="pubmed">17290308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Reilly KE, et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500–1508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3193604</ArticleId>
            <ArticleId IdType="pubmed">16452206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol. 2010;22:169–176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2854285</ArticleId>
            <ArticleId IdType="pubmed">19945836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shor B, et al.  A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res. 2008;68:2934–2943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18413763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A. 2008;105:17414–17419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2582304</ArticleId>
            <ArticleId IdType="pubmed">18955708</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMahon LP, Choi KM, Lin TA, Abraham RT, Lawrence JC., Jr The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7428–7438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC135667</ArticleId>
            <ArticleId IdType="pubmed">12370290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman ME, et al.  Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7:e38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2637922</ArticleId>
            <ArticleId IdType="pubmed">19209957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chresta CM, et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010;70:288–298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20028854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Martinez JM, et al.  Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) Biochem J. 2009;421:29–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2708931</ArticleId>
            <ArticleId IdType="pubmed">19402821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu K, et al.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009;69:6232–6240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19584280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nardella C, et al.  Differential requirement of mTOR in postmitotic tissues and tumorigenesis. Sci Signal. 2009;2:ra2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2906144</ArticleId>
            <ArticleId IdType="pubmed">19176516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes MR, et al.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med. 2010;16:205–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4017764</ArticleId>
            <ArticleId IdType="pubmed">20072130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelman JA, et al.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14:1351–1356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2683415</ArticleId>
            <ArticleId IdType="pubmed">19029981</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan QW, et al.  A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell. 2006;9:341–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2925230</ArticleId>
            <ArticleId IdType="pubmed">16697955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu TJ, et al.  NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther. 2009;8:2204–2210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2752877</ArticleId>
            <ArticleId IdType="pubmed">19671762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brachmann SM, et al.  Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A. 2009;106:22299–22304.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2799764</ArticleId>
            <ArticleId IdType="pubmed">20007781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chiarini F, et al.  Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res. 2009;69:3520–3528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3836286</ArticleId>
            <ArticleId IdType="pubmed">19351820</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McMillin DW, et al.  Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009;69:5835–5842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19584292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. Science. 2010;328:321–326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3607354</ArticleId>
            <ArticleId IdType="pubmed">20395504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabrizio P, Pozza F, Pletcher SD, Gendron CM, Longo VD. Regulation of longevity and stress resistance by Sch9 in yeast. Science. 2001;292:288–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11292860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaeberlein M, et al.  Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science. 2005;310:1193–1196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16293764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia K, Chen D, Riddle DL. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development. 2004;131:3897–3906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15253933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vellai T, et al.  Genetics: influence of TOR kinase on lifespan in C. elegans. Nature. 2003;426:620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14668850</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjedov I, et al.  Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab. 2010;11:35–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2824086</ArticleId>
            <ArticleId IdType="pubmed">20074526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapahi P, et al.  Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol. 2004;14:885–890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2754830</ArticleId>
            <ArticleId IdType="pubmed">15186745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison DE, et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2786175</ArticleId>
            <ArticleId IdType="pubmed">19587680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selman C, et al.  Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 2009;326:140–144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4954603</ArticleId>
            <ArticleId IdType="pubmed">19797661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen M, et al.  Lifespan extension by conditions that inhibit translation in Caenorhabditis elegans. Aging Cell. 2007;6:95–110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17266679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan KZ, et al.  Inhibition of mRNA translation extends lifespan in Caenorhabditis elegans. Aging Cell. 2007;6:111–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2745345</ArticleId>
            <ArticleId IdType="pubmed">17266680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steffen KK, et al.  Yeast life span extension by depletion of 60s ribosomal subunits is mediated by Gcn4. Cell. 2008;133:292–302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2749658</ArticleId>
            <ArticleId IdType="pubmed">18423200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Syntichaki P, Troulinaki K, Tavernarakis N. eIF4E function in somatic cells modulates ageing in Caenorhabditis elegans. Nature. 2007;445:922–926.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17277769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy CT, et al.  Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans. Nature. 2003;424:277–283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12845331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hansen M, et al.  A role for autophagy in the extension of lifespan by dietary restriction in C. elegans. PLoS Genet. 2008;4:e24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2242811</ArticleId>
            <ArticleId IdType="pubmed">18282106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toth ML, et al.  Longevity pathways converge on autophagy genes to regulate life span in Caenorhabditis elegans. Autophagy. 2008;4:330–338.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18219227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Cuervo AM. Restoration of chaperone-mediated autophagy in aging liver improves cellular maintenance and hepatic function. Nat Med. 2008;14:959–965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2722716</ArticleId>
            <ArticleId IdType="pubmed">18690243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He S, Nakada D, Morrison SJ. Mechanisms of stem cell self-renewal. Annu Rev Cell Dev Biol. 2009;25:377–406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19575646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janzen V, et al.  Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature. 2006;443:421–426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16957735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molofsky AV, et al.  Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature. 2006;443:448–452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2586960</ArticleId>
            <ArticleId IdType="pubmed">16957738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C, Liu Y, Zheng P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci Signal. 2009;2:ra75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4020596</ArticleId>
            <ArticleId IdType="pubmed">19934433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yilmaz OH, et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006;441:475–482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16598206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grandison RC, Piper MD, Partridge L. Amino-acid imbalance explains extension of lifespan by dietary restriction in Drosophila. Nature. 2009;462:1061–1064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2798000</ArticleId>
            <ArticleId IdType="pubmed">19956092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nobukuni T, et al.  Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci U S A. 2005;102:14238–14243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1242323</ArticleId>
            <ArticleId IdType="pubmed">16176982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chang YY, Neufeld TP. An Atg1/Atg13 complex with multiple roles in TOR-mediated autophagy regulation. Mol Biol Cell. 2009;20:2004–2014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2663935</ArticleId>
            <ArticleId IdType="pubmed">19225150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berchtold D, Walther TC. TORC2 plasma membrane localization is essential for cell viability and restricted to a distinct domain. Mol Biol Cell. 2009;20:1565–1575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2649262</ArticleId>
            <ArticleId IdType="pubmed">19144819</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
